Clinical Trial Update: Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)

View source ↗

Summary

Clinical trial update describing analysis of a biomarker signature in multiple sclerosis patients treated with fingolimod (Gilenya).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: McGill University | Conditions: Multiple Sclerosis | Status: UNKNOWN